@espn@stephenasmith@stephenasmith needs to go to journalism school. He is a degenerate sports journalist, projecting his inadequacies on his thoughtful co-hosts that put up with his Jerry Springer persona.
@MRusselltennis@taylorfritzfanp as a fellow fan from SD. We are routing for you, I wonder if you add in a looping backhand with placement to move your opponent around rather than the pressure of a tight lower backhand, that may find the net?
@taylorfritzfanp as a fellow fan from SD. We are routing for you, I wonder if you add in a looping backhand with placement to move your opponent around rather than the pressure of a tight lower backhand, that may find the net?
Just published @NEJM
During Omicron, the 2-shot mRNA vaccine effectiveness among >250,000 children age 5 to 11 years old:
vs hospitalizations was very high—83%
vs PCR confirmed infections 65%
https://t.co/7HigzbbVey
@SquawkCNBC for Covid guests: are they concerned Pharma is not leveraging AI / informatics to predict a pan-vaccine for Covid towards continued revenue from yearly vaccines?
Bookends to a very fulfilling career: 1st RP patient (Aug 1989) still alive & cancer free @ age 88; last RP (Sep 2021) hit the trifecta 5 weeks post-op. The Emporium is now officially on hiatus. Elvis has left the building... @CleClinicUro@CleClinicNeph#TeamGUKI
Too little, too late, too flawed.
Sound familiar?
UK (and US homology) on the failure of its public health response to #COVID19
https://t.co/CgXX093t1q @bmj_latest by @GabrielScally @Bobbiedoc Kamran Abbasi
@LifeSciVC “Why are we here? We’re here to make medicines that help patients, and this conference week is supposed to rally us all around that mission. But I didn’t hear a lot about patients and impact this year.”
@LifeSciVC “Given the speed-dating nature of most discussions, almost all JPM interactions are superficial at best.”-Amen and thanks for saying what many of us have come to realize regarding the ROI and relevance of attending JPM year after year.
The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference. More concerned than ever about the value of the JPM week and what it says about our industry. https://t.co/PBn4DvFoss #JPM19#JPMHC19
This Boston startup is developing technology using live cell phenotyping for the risk-stratification of #ProstateCancer@Cellanyx https://t.co/c6AFhTwPQa
Calling all #FinTech startups: applications for @MassChallengeFT are now open! @MassChallenge’s newest zero-equity accelerator can grow your #startup w/ 1:1 industry partnerships + expert mentors + up to $250K in cash. Apply by 10/12 at 12:00PM ET: https://t.co/xhvzJyF2sP
Thank you to @theNCI@BidenCancer moonshot program for funding our initiative @BCMCancer. Thanks to @PCFnews@PCF_Science helping us lay the groundwork for this critical work on African American prostate cancer through the VA PCF Challenge Grant!
Congratulations Jim Allison on winning the 2018 #NobelPrize in Medicine! PCF was an early funder of Allison's #immunotherapy work in #ProstateCancer. Since then, 1000's of patients have been helped, and the promising fields of immunotherapy and precision medicine have ballooned.